liposomal paclitaxel

Phase 2Small molecule

SShandong Luye Pharmaceutical Co., Ltd.

liposomal paclitaxel is one of 73 small molecule programs targeting Esophageal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Esophageal CarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Imjudo

AstraZeneca

Preclinical

5 2

liposomal paclitaxel

SShandong Luye Pharmaceutical Co., Ltd.

Phase 2

1 3

Remeron

OOrganon and Co

Preclinical

1 4

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 5

Vidaza

Bristol-Myers Squibb

Preclinical

1 6

REGN2810

Regeneron

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatment

1 9

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

3 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT05766800

Q2 2030

Phase 3Recruiting

Neoadjuvant Treatment

NCT06102395

Clinical

Trials by Indication[1]

Paclitaxel2 trials

Pharmacokinetics Study of Liposomal Paclitaxel in Humans

Completed·SShandong Luye Pharmaceutical Co., Ltd.·Phase 4·NCT00606515·16 enrolled

Clinical Study of Liposomal Paclitaxel in Chinese Patients

Unknown status·NNanjing Sike Pharmaceutical Co., Ltd.·Phase 1·NCT00881101·15 enrolled

Cancer of the Esophagus1 trial

PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00016900

Esophageal Carcinoma1 trial

Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma

Completed·SSun Yat-sen University·Phase 2·NCT02861690·72 enrolled

Non-Small Cell Lung Cancer1 trial

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT05766800·100 enrolled

Neoadjuvant Treatment1 trial

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Recruiting·—·Phase 3·NCT06102395·272 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for liposomal paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — liposomal paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for liposomal paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Luye Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShandong Luye Pharmaceutical Co., Ltd.

liposomal paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2030

Trials by Indication[1]

Paclitaxel2 trials

Cancer of the Esophagus1 trial

Esophageal Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Neoadjuvant Treatment1 trial

References

Drug Info

Quick Facts

Related News